Slot, Evelien
Boers, Ruben
Boers, Joachim
van IJcken, Wilfred F. J.
Tibboel, Dick
Gribnau, Joost
Rottier, Robbert
de Klein, Annelies http://orcid.org/0000-0002-1513-4787
Funding for this research was provided by:
Stichting Vrienden van het Sophia (2017-010/WO)
Koninklijke Nederlandse Akademie van Wetenschappen (1453/WetF/TMB17/329)
Article History
Received: 21 April 2021
Accepted: 14 July 2021
First Online: 29 July 2021
Declarations
:
: The authors declare no conflict of interest or financial interests except for RB, JB, WVI and JG, who report being shareholder in Methylomics B.V., a commercial company that applies MeD-seq to develop methylation markers for cancer staging.